Key Takeaways
- Penn State Health Milton S. Hershey Medical Center performed its first heart transplant using the TransMedics Organ Care System, also known as “Heart‑in‑a‑Box.”
- The device keeps donor hearts beating, warm, and oxygenated during transport, allowing functional assessment and extending viable preservation time beyond traditional cold storage.
- Surgery was led by Dr. Balakrishnan Mahesh; recipient Marion Lehman of Cogan Station, PA, is recovering well.
- The technology enabled transport of the donor heart for more than three hours, expanding the geographic reach for organ procurement.
- The case also marked the center’s first donation after circulatory death (DCD) heart transplant, a milestone for enlarging the donor pool.
- Dr. John Boehmer, director of the Advanced Heart Failure Transplant Program, highlighted the system’s role in improving decision‑making and increasing transplant opportunities.
- Penn State Hershey’s heart transplant program consistently ranks among the nation’s best; adoption of Heart‑in‑a‑Box reinforces its commitment to innovative therapies.
- The advancement promises to reduce organ discard due to distance or time constraints and may inspire wider adoption of normothermic perfusion across transplant centers.
- Ongoing research will focus on long‑term outcomes, cost‑effectiveness, and expanding the system to other organs.
Overview of the Milestone Transplant
On Saturday, June 13, 2026, Penn State Health Milton S. Hershey Medical Center achieved a historic milestone by completing its first heart transplant utilizing the TransMedics Organ Care System, colloquially called “Heart‑in‑a‑Box.” The procedure took place in the center’s state‑of‑the‑art operating suite and was announced by Penn State Health News on June 22, 2026. This event represents not only a technical achievement for the institution but also a potential paradigm shift in how donor hearts are preserved, evaluated, and allocated nationwide.
How Heart‑in‑a‑Box Differs from Traditional Cold Storage
Unlike the conventional method of storing donor hearts in ice‑cold static solution, the Heart‑in‑a‑Box system maintains the organ in a warm, oxygen‑rich, perfusate‑filled environment that mimics physiological conditions. The heart continues to beat and metabolize, allowing clinicians to monitor real‑time parameters such as contractility, coronary flow, and lactate clearance. This normothermic perfusion approach reduces ischemic injury, provides an opportunity to assess organ viability before implantation, and can safely extend the preservation window well beyond the typical four‑hour limit of cold storage.
Surgical Team and Patient Outcome
Dr. Balakrishnan Mahesh, a cardiac and transplant surgeon with extensive experience in mechanical circulatory support and heart transplantation, directed the procurement and implantation of the donor heart. The recipient, Marion Lehman of Cogan Station, Pennsylvania, suffered from end‑stage heart failure and received the Heart‑in‑a‑Box–preserved organ. Post‑operative reports indicate that Ms. Lehman is recovering well, with stable hemodynamics, no evidence of primary graft dysfunction, and early signs of functional improvement—a testament to the organ’s preserved quality.
Extended Viable Travel Time and Geographic Reach
One of the most immediate benefits observed in this case was the ability to extend the viable travel time for the donor heart to more than three hours. Traditional cold storage often limits transport to shorter distances due to the progressive decline in organ function during ischemia. By keeping the heart metabolically active, the Heart‑in‑a‑Box system mitigates time‑related deterioration, enabling transplant teams to consider donors located farther away. This expansion can significantly increase the pool of potential hearts for patients in regions with limited local donor availability.
First Donation After Circulatory Death (DCD) Heart Transplant
The procedure also marked Milton S. Hershey Medical Center’s inaugural donation after circulatory death (DCD) heart transplant. In DCD donation, the heart is retrieved after circulatory arrest has been declared, a scenario previously considered unsuitable for heart transplantation due to concerns about warm ischemic injury. The Heart‑in‑a‑Box’s capacity to resuscitate and assess the arrested heart ex vivo allowed the team to evaluate functional recovery and deem the organ transplantable. This breakthrough opens a new avenue for augmenting the donor pool, particularly as DCD protocols become more prevalent for other organs.
Clinical Perspective from Program Leadership
Dr. John Boehmer, director of the Advanced Heart Failure Transplant Program at Penn State Hershey, lauded the technology as a “significant advancement for our heart transplant program.” He emphasized that the ability to monitor the heart while it is functioning outside the body provides surgeons with richer data, leading to more informed acceptance criteria for marginal organs. Consequently, more patients awaiting transplantation may receive a second chance at life, reducing waitlist mortality and improving overall program efficacy.
Institutional Excellence and Commitment to Innovation
Penn State Hershey’s heart transplant program consistently ranks among the best in the nation for observed versus expected pre‑transplant mortality and long‑term survival outcomes. As the sole heart transplant center serving central Pennsylvania, the institution’s adoption of Heart‑in‑a‑Box underscores its dedication to integrating cutting‑edge therapies into clinical practice. This commitment not only benefits current patients but also positions the center as a leader in research and training for the next generation of transplant surgeons and perfusion specialists.
Broader Implications for the Transplant Field
The successful use of normothermic perfusion at Penn State Hershey adds to a growing body of evidence supporting the broader adoption of devices like the TransMedics Organ Care System across solid‑organ transplantation. Potential advantages include decreased organ discard rates, improved post‑transplant graft function, and the possibility of repairing marginal organs ex vivo. Challenges remain, notably the high capital and operative costs associated with perfusion systems, the need for specialized staff training, and the establishment of standardized protocols for organ assessment. Ongoing multicenter trials and health‑economic analyses will be essential to determine the long‑term cost‑effectiveness and scalability of this technology.
Conclusion and Future Outlook
The first Heart‑in‑a‑Box–assisted heart transplant at Penn State Health Milton S. Hershey Medical Center represents a convergent achievement of surgical expertise, technological innovation, and forward‑thinking organ‑donation policy. By enabling functional evaluation, extending preservation times, and facilitating DCD heart recovery, the system promises to expand access to life‑saving transplants for countless patients awaiting a donor heart. As the medical community continues to refine perfusion strategies and address logistical and financial barriers, the Heart‑in‑a‑Box may become a cornerstone of modern transplant medicine, heralding a new era where distance and time are less likely to preclude the gift of life.